- Aytu BioScience (AYTU +0.9%) grabs the U.S. commercial rights to Toronto, Canada-based Acerus Pharmaceuticals' Natesto (testosterone) Nasal Gel for replacement therapy in men with low testosterone. The company intends to expand its salesforce and launch the product in July.
- Under the terms of the deal, Acerus will receive an upfront payment of $2M and additional payments valued at up to $6M in fiscal 2017. The maximum milestone payable is associated with achieving $125M in annual U.S. sales. Aytu has also agreed to purchase $2M of Acerus common stock.